ClearPoint Neuro

List of Diagnostics & Research Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 520.14
0.76 0.15
1.70M
385.72M
US$ 200.630B
US$ 234.62
1.93 0.83
2.04M
737.90M
US$ 173.130B
US$ 122.57
2.99 2.50
2.48M
387.64M
US$ 47.510B
US$ 470.83
0.99 0.21
365,174
82.90M
US$ 39.030B
US$ 201.37
2.40 1.21
835,328
185.55M
US$ 37.360B
US$ 118.22
1.96 1.69
3.20M
295.70M
US$ 34.960B
US$ 207.31
8.22 4.13
2.01M
158.10M
US$ 32.780B
US$ 1.00
3.34 0.25
82,684
22.02M
US$ 29.350B
US$ 216.98
4.54 2.14
647,725
88.60M
US$ 19.220B
US$ 221.45
5.60 2.59
741,642
81.93M
US$ 18.140B
US$ 258.77
2.73 1.07
402,378
59.03M
US$ 15.280B
US$ 135.56
1.51 1.13
897,336
112.01M
US$ 15.180B
US$ 83.84
0.00 0.00
1.36M
180.39M
US$ 15.120B
US$ 114.77
0.00 0.00
0
126.41M
US$ 14.510B
US$ 46.48
0.70 1.53
888,830
228.04M
US$ 10.600B
US$ 200.68
4.34 2.21
412,003
51.18M
US$ 10.270B
US$ 212.06
5.17 2.50
315,514
30.50M
US$ 6.470B
US$ 88.67
-0.41 -0.46
762,239
68.33M
US$ 6.060B
US$ 86.16
0.51 0.60
211,703
66.63M
US$ 5.740B
US$ 48.81
-0.48 -0.97
768,914
114.30M
US$ 5.580B
US$ 41.56
0.01 0.02
1.74M
103.65M
US$ 4.310B
US$ 14.77
0.58 4.09
635,776
282.52M
US$ 4.170B
US$ 18.51
-0.02 -0.11
1.92M
216.22M
US$ 4.000B
US$ 13.49
0.63 4.90
4.48M
249.89M
US$ 3.370B
US$ 32.39
1.00 3.19
1.58M
102.76M
US$ 3.330B
US$ 19.91
0.57 2.95
43,024
124.34M
US$ 2.480B
US$ 17.98
0.33 1.87
754,710
127.58M
US$ 2.290B
US$ 23.43
0.33 1.43
631,183
81.56M
US$ 1.910B
US$ 30.38
0.61 2.05
406,049
58.35M
US$ 1.770B
US$ 30.03
-0.33 -1.09
333,576
47.73M
US$ 1.430B
US$ 119.84
-0.01 -0.01
371,381
10.91M
US$ 1.310B
US$ 40.33
-0.37 -0.91
330,155
29.70M
US$ 1.200B
US$ 45.70
1.78 4.05
45,714
24.61M
US$ 1.120B
US$ 1.45
0.05 3.57
3.04M
772.65M
US$ 1.120B
US$ 16.31
0.30 1.87
957,190
57.15M
US$ 932.120M
US$ 22.73
1.68 7.98
234,074
26.69M
US$ 606.660M
US$ 2.05
0.07 3.54
2.61M
288.75M
US$ 591.940M
US$ 8.13
0.12 1.50
494,543
53.79M
US$ 437.310M
US$ 1.07
0.01 0.94
8.12M
260.68M
US$ 278.930M
US$ 2.42
-0.16 -6.20
159,318
102.68M
US$ 248.490M
US$ 0.79
0.06 8.44
15.48M
306.79M
US$ 243.590M
US$ 1.69
0.15 9.74
455,042
121.56M
US$ 205.440M
US$ 2.37
0.05 2.16
380,606
78.38M
US$ 185.760M
US$ 5.99
0.18 3.10
244,780
25.76M
US$ 154.300M
US$ 2.21
0.02 0.91
77,456
49.66M
US$ 109.750M
US$ 4.03
0.23 6.05
224,099
27.04M
US$ 108.970M
US$ 1.35
-0.04 -2.88
41,992
78.46M
US$ 105.920M
US$ 4.01
0.01 0.25
96,625
26.36M
US$ 105.700M
US$ 1.54
0.06 4.05
216,223
63.18M
US$ 97.300M
US$ 3.25
0.03 0.78
23,710
29.65M
US$ 96.360M
US$ 5.79
0.14 2.48
38,309
14.83M
US$ 85.870M
CA$ 0.31
0.01 3.39
9,500
278.55M
CA$ 84.960M
US$ 0.88
-0.01 -1.44
5,212
90.60M
US$ 79.800M
US$ 2.55
0.04 1.59
180,935
31.09M
US$ 79.280M
US$ 2.71
-0.06 -2.17
55,035
28.50M
US$ 77.240M
US$ 0.75
0.06 7.91
96,061
99.83M
US$ 74.870M
US$ 0.41
0.05 14.14
175,383
164.32M
US$ 66.580M
US$ 2.24
-0.14 -5.88
162,563
25.90M
US$ 58.020M
0.58
-0.02 -3.33
2,500
98.39M
57.070M
US$ 3.09
-0.06 -1.90
5,233
16.83M
US$ 52.000M
US$ 0.98
0.08 8.41
66,808
38.21M
US$ 37.450M
US$ 1.09
0.00 0.00
78,197
30.26M
US$ 32.980M
US$ 4.75
-0.05 -1.04
21,890
5.72M
US$ 27.170M
0.32
0.00 0.00
2,500
83.29M
26.650M
US$ 0.90
0.01 1.12
20,802
27.60M
US$ 24.840M
US$ 2.98
-0.01 -0.33
29,485
8.33M
US$ 24.820M
US$ 0.95
-0.0078 -0.81
40,952
19.24M
US$ 18.310M
CA$ 0.31
0.04 15.09
6,080
59.82M
CA$ 18.250M
CA$ 0.19
0.00 0.00
57,500
98.62M
CA$ 18.240M
0.33
0.01 3.12
5,710
51.86M
17.110M
US$ 0.45
0.00 0.00
0
36.73M
US$ 16.610M
US$ 1.26
-0.01 -0.79
38,263
12.91M
US$ 16.270M
US$ 1.82
0.00 0.00
7,815
8.52M
US$ 15.510M
US$ 1.72
0.08 4.88
27,841
8.71M
US$ 14.980M
US$ 0.62
0.03 5.54
29,341
23.44M
US$ 14.470M
CA$ 0.04
-0.01 -22.22
294,000
406.25M
CA$ 14.220M
US$ 1.34
-0.05 -3.60
39,903
9.03M
US$ 12.100M
US$ 1.50
0.10 7.14
37,180
7.48M
US$ 11.220M
US$ 1.78
0.23 14.84
69,559
5.85M
US$ 10.410M
CA$ 0.10
0.005 5.56
1,000
87.16M
CA$ 8.280M
CA$ 0.07
0.00 0.00
10,694
106.39M
CA$ 6.920M
US$ 0.46
-0.03 -5.66
1.26M
13.89M
US$ 6.420M
US$ 2.12
-0.03 -1.40
29,620
2.21M
US$ 4.690M
US$ 0.70
-0.0012 -0.17
36,438
6.12M
US$ 4.290M
US$ 0.70
0.04 5.45
42,962
5.30M
US$ 3.690M
US$ 0.10
-0.004 -3.77
15.96M
24.89M
US$ 2.540M
0.02
0.00 0.00
0
118.77M
1.780M
US$ 2.13
0.08 3.90
50,851
592,906
US$ 1.260M
US$ 0.88
-0.04 -4.35
28,554
-
US$ -

Latest News From Diagnostics & Research Stocks


Castle Biosciences to Share New Data on DecisionDx®-Melanoma and DecisionDx®-UM at the 2023 ASCO Annual Meeting

FRIENDSWOOD, Texas / Jun 03, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data on DecisionDx®-Melanoma and DecisionDx®-UM will be shared during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6. DecisionDx-Melanoma is the Company’s genomic risk-stratification test for patients with cutaneous melanoma, and D... Read more


Illumina's Board of Directors elects two experienced Independent Directors to Board

Stephen P. MacMillan, Hologic CEO, named non-executive Chair of Illumina's Board Scott B. Ullem, CFO of Edwards Lifesciences, also named to Board SAN DIEGO, June 2, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a series of governance changes consistent with the goal of enhancing long-term shareholder value. The Board has elected two new independent board members to join the... Read more


Illumina unveils AI software to predict disease-causing genetic mutations in patients

Published findings demonstrate PrimateAI-3D's ability to improve genetic risk prediction and drug target discovery using primate DNA and advanced artificial intelligence SAN DIEGO, June 1, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the new PrimateAI-3D, an artificial intelligence (AI) algorithm that predicts with unprecedented accuracy disease-causing genetic mutations in patients.... Read more


Dexcom Announces Upcoming Conference Presentation

SAN DIEGO / Jun 01, 2023 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at William Blair's 43rd Annual Growth Stock Conference on Wednesday, June 7th. The live presentation is scheduled to begin at approximately 1:40 PM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at inves... Read more


CareDx Demonstrates Innovation Leadership at 2023 Transplant Congress

Record Number of 65 Abstracts Showcasing CareDx Innovation Including Data Showing Clinical Utility of AlloSure Kidney to Guide Immunosuppression Management Experts Review Advancements in Artificial Intelligence and Molecular Diagnostics During CareDx Symposium BRISBANE, Calif. / Jun 01, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value... Read more


Myriad Genetics Highlights Latest Oncology Portfolio Advancements and New Data at ASCO 2023

SALT LAKE CITY, June 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be highlighting new studies and the recent expansion of its Precise™ Oncology Solutions portfolio at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting from June 2-6, 2023. Myriad has recently made several advancements supporting its oncology footprint including hiring oncology experts to its leadership team... Read more


Biodesix Announces Three Abstracts to Be Presented at ASCO 2023 Annual Meeting

BOULDER, Colo. / Jun 01, 2023 / Business Wire / Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that three new scientific abstracts will be presented as part of the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting including a poster presented by Friends of Cancer Research (FoCR) featuring genomic data contributed by Biodesix and other organizations. This poster highlights long... Read more


Labcorp Plasma Focus Liquid Biopsy Test Now Available

Liquid biopsy test for cancer patients enables oncologists to identify targeted therapies and improve care BURLINGTON, N.C., May 31, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, has launched Labcorp Plasma Focus, a new liquid biopsy test enabling targeted therapy selection for patients with advanced or metastatic solid tumors. The test allows treating oncologists to evaluate circulating cell-free DNA (cfDNA) released by tumor cells... Read more


Wheeler Bio and Charles River Laboratories Announce Agreement to Build and Operate RightSource(SM) Laboratory

RightSourceSM is Charles River's insourced, purpose-built lab offering that provides industry-leading expertise conveniently placed within a Wheeler Bio's new cGMP drug substance facility. OKLAHOMA CITY, May 31, 2023 /PRNewswire/ -- Wheeler Bio, Inc., a contract development and manufacturing organization (CDMO), and Charles River Laboratories International, Inc. (NYSE: CRL) today announced an agreement to implement RightSourceSM at Wheeler Bio's current good... Read more


Neogen® Launches New Assays for Histamine Detection

LANSING, Mich., May 31, 2023 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) announced today that it has launched two new assays for the detection of histamine, Reveal® for Histamine and Reveal Q+ for Histamine. Reveal and Reveal Q+ assays are easy-to-use lateral flow tests that utilize a simple water extraction method, providing results in a matter of minutes and eliminating the need to dispose of any chemicals, as is needed with other commercially available histamine... Read more


Charles River Laboratories and Wheeler Bio Announce Agreement to Build and Operate RightSourceSM Laboratory

RightSource is Charles River’s insourced, purpose-built lab offering that provides industry-leading expertise conveniently placed within a client’s facility WILMINGTON, Mass. / May 31, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and Wheeler Bio, Inc., a contract development and manufacturing organization (CDMO), today announced an agreement to implement RightSourceSM at Wheeler Bio’s current good manufacturing practice (CGMP)... Read more


Castle Biosciences: IDgenetix® Shown to Significantly Improve Medication Response and Remission Rates in Patients with Major Depressive Disorder

In the study, patients whose medication management was guided by IDgenetix achieved a 35% increase in medication response and a 64% increase in remission compared to patients whose medication was not guided by the test FRIENDSWOOD, Texas / May 31, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced real-world study data demonstrating that use of IDgenetix® to guide... Read more


Twist Bioscience and CeGaT Launch RNA Fusion Panel to Advance Oncology and Precision Medicine Research

RNA fusions can be used as biomarkers to identify cancer sub-types and monitor for residual disease SOUTH SAN FRANCISCO, Calif. / May 31, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and CeGaT GmbH, a global provider of sequencing services for research, clinical studies, and human genetic diagnostics, today announced the launch... Read more


BioMark Diagnostics Announces the U.S. Patent and Trademark Office Granted Patent with Claims Covering Its Lung Cancer Liquid Biopsy Assay

The new family of patent granted by USPTO strengthens BioMark's global intellectual property position in liquid biopsy and early cancer detection Vancouver, British Columbia--(Newsfile Corp. - May 31, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that the U.S. Patent and Trademark Office (USPTO) has issued U.S.... Read more


DermTech Surpasses 200,000 Cumulative Billable Samples for the DermTech Melanoma Test (DMT)

SAN DIEGO / May 31, 2023 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that the DermTech Melanoma Test (DMT) has tested more than 200,000 suspicious pigmented lesions. The DMT uses non-invasive Smart Stickers™ to test for select genomic markers associated with melanoma, one of the deadliest forms of skin cancer. With a negative predictive... Read more


Mainz Biomed Expands Commercial Footprint into Poland

Total addressable market in Poland is estimated at 21 million patients BERKELEY, Calif. and MAINZ, Germany, May 31, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the establishment of a commercial partnership for ColoAlert® with TESTDNA Sp. z o.o. Sp. k. Katowice, Poland, a leading independent laboratory in Poland.... Read more


Guardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting

New research further confirms value of interrogating epigenomic signals with Guardant Infinity™ platform to identify novel biomarker targets and predict treatment resistance PALO ALTO, Calif. / May 31, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that the company and its research collaborators will present data from 17 studies that highlight the contribution of Guardant blood tests and real-world data... Read more


VolitionRx Announces Proposed Underwritten Public Offering of Common Stock

HENDERSON, Nev., May 31, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has commenced an underwritten public offering of shares of its common stock. In addition, Volition intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the offering at the public offering price, less underwriting... Read more


Adam Brufsky, MD, PhD, FACP Named Oncology Scientific Advisor to Myriad Genetics

SALT LAKE CITY, May 31, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has named Adam Brufsky, MD, PhD, FACP, as Scientific Advisor to its oncology business unit. In his new role, Dr. Brufsky is responsible for guiding clinical development and medical affairs to further elevate Myriad’s Precise™ Oncology Solutions portfolio. “Adam is an accomplished leader and respected expert... Read more


Neogen to Participate in the 43rd Annual William Blair Growth Stock Conference

LANSING, Mich., May 30, 2023 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) announced today that the Company will participate in the 43rd Annual William Blair Growth Stock Conference in Chicago, Illinois, on Tuesday, June 6, 2023. John Adent, Neogen's President and Chief Executive Officer, will present at 4:00 p.m. Central Time. Presentation materials will be posted to the Neogen Investor Relations website on the morning of June 6. To access them, along with the... Read more


Spectral Medical Provides Update on Favorable Tigris Clinical Trial Enrollment

Reports significant uptick in enrollment activities Tigris trial enrollment at 61 patients TORONTO, May 30, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an enrollment update on Tigris, the Company’s follow-on study designed to build on knowledge gained from the earlier EUPHRATES trial, which evaluated the... Read more


Illumina: Real-world study data reveals better outcomes for cancer patients who receive comprehensive genomic testing

Data also shows that current standard-of-care testing for cancer patients falls short in multiple ways SAN DIEGO, May 30, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced some of the latest data on the impact of comprehensive genomic profiling (CGP) for oncology patients, which will be presented at the American Society of Clinical Oncology's Annual Meeting June 2–6 in Chicago. In addition... Read more


HeartBeam Enters into Strategic Alliance Agreement with Samsung

SANTA CLARA, Calif. / May 30, 2023 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform intended for patient use at home, today announced that it has entered into a Strategic Alliance Agreement (SAA) with Samsung, extending the existing SAA between LIVMOR and Samsung. HeartBeam acquired the assets of LIVMOR earlier this year. Under the terms of the agreement, HeartBeam... Read more


T2 Biosystems Announces Second Largest Sepsis-Driven Instrument Sale in Company History

LEXINGTON, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the second largest sale of sepsis-driven T2Dx® Instruments in Company history. T2 Biosystems’ distribution partner, Biomedica Poland, secured a multi-year contract for T2Dx Instruments and sepsis test panels that are expected to be deployed in selected hospitals across... Read more


SeqLL Enters into a Definitive Merger Agreement with Lyneer Staffing Solutions and Atlantic Acquisition

BILLERICA, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (Nasdaq: SQL, SQLLW), a technology company providing life sciences instrumentation and research services, today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) with Lyneer Investments, LLC (“Lyneer”), the indirect parent company of Lyneer Staffing Solutions, LLC and Atlantic Acquisition Corp. (“Atlantic”), and related parties,... Read more


New Natera Data to be Presented at the 2023 ASCO Annual Meeting in 13 Studies Across Multiple Cancer Types

Highlights include oral presentations in Sarcoma and CRC; immunotherapy monitoring data from the Phase 3 EMPOWER-Lung 1 study; updates from the CIRCULATE-Japan study in CRC AUSTIN, Texas / May 30, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, will be presented at the 2023 American Society of Clinical... Read more


NeoGenomics to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO

FT. MYERS, FL / ACCESSWIRE / May 30, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced new data supporting its cancer tests and treatment guidance tools will be showcased in five poster presentations at the 2023 American Society of Clinical Oncology (ASCO®) Annual Meeting taking place June 2-6 in Chicago, Illinois. "Together with our collaborators from leading medical institutions, NeoGenomics... Read more


PacBio Announces the Appointment of Olga Troyanskaya from Princeton University to the Scientific Advisory Board

Current Member, Jay Shendure, is Appointed Chair   MENLO PARK, Calif., May 30, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of Olga Troyanskaya, Ph.D., Professor of Computer Science and the Lewis Sigler Institute for Integrative Genomics at Princeton University to PacBio's Scientific Advisory Board (SAB) and Jay Shendure, Ph.D. as Chair. Dr. Shendure... Read more


Burning Rock Biotech Reports First Quarter 2023 Financial Results

GUANGZHOU, China, May 30, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2023. Recent Business Updates Minimal Residual Disease (MRD) Results of the MEDAL (MEthylation Based Dynamic Analysis for Lung... Read more


Guardant Health Receives Regulatory Approval from Singapore's Health Sciences Authority for Guardant360® CDx blood test for patients with advanced solid cancers

Guardant360® CDx is a comprehensive genomic profiling blood test that provides critical information to help inform personalized treatment decisions for patients with advanced solid cancers   The liquid biopsy test is also approved as a companion diagnostic for TAGRISSO® (osimertinib) in non-small cell lung cancer   This is the first blood test to be approved by Singapore's Health Sciences Authority for comprehensive genomic profiling for all solid tumor... Read more


Neuronetics Announces Increased TMS Access Through BlueCross BlueShield Of Michigan

MALVERN, Pa., May 26, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced a healthcare policy update from BlueCross BlueShield (BCBS) of Michigan that expands eligibility for depression patients to receive transcranial magnetic stimulation (TMS). This policy change increases patient... Read more


Exact Sciences Presents New Long-Term Patient Outcomes in Multi-Cancer Early Detection and Breast Cancer Recurrence Testing at ASCO® 2023

Exact Sciences' approach in multi-cancer early detection (MCED) confirmed in first-ever, long-term, follow-up data from an MCED trial1-2 Surveillance, Epidemiology, and End Results (SEER) program analysis shows continued, long-term confidence in prognostic value of the Oncotype DX Breast Recurrence Score® 3 New modeling data show superior health outcomes in colorectal cancer screening with Cologuard® compared to blood-based tests, including lower mortality and more... Read more


New Research Insights to be Presented by Invitae at the 2023 ASCO Annual Meeting Reinforce the Critical Role of Germline Genetic Testing in Oncology

Study findings confirm the importance of improving education among clinicians and streamlining processes to increase adoption of testing in routine cancer care SAN FRANCISCO, May 26, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced nine studies to be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago from June 2-6, 2023. The new research insights highlight innovations... Read more


Castle Biosciences’ Abstracts at Digestive Disease Week (DDW) Annual Meeting Selected as “Posters of Distinction” by the American Gastroenterological Association (AGA) Institute Council

New data demonstrate the risk-stratification performance and potential of the TissueCypher® Barrett’s Esophagus test to guide risk-aligned patient care decisions FRIENDSWOOD, Texas / May 26, 2023 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its three posters at the recent DDW Annual Meeting were honored as “Posters of Distinction” by the AGA Institute... Read more


Mettler-Toledo Announces Webcast of Presentation at the Jefferies Healthcare Conference

Columbus, OH, May 25, 2023 (GLOBE NEWSWIRE) -- Mettler-Toledo International Inc. (NYSE:MTD) today announced the webcast of its presentation at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 8:30 a.m Eastern Time.  To hear a live webcast of the presentation, visit the investor relations page on the Company’s Web site at www.investors.mt.com.  A replay of the webcast will be available. METTLER TOLEDO (NYSE: MTD) is a leading global... Read more


PacBio to Present at Upcoming Investor Conferences

MENLO PARK, Calif., May 25, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the following upcoming investor conferences: Bernstein's 39th Annual Strategic Decisions Conference on Thursday, June 1, 2023, at 2:30 PM ET in New York, NY Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13, 2023, at 8:00 AM PT in Dana Point, CA Live... Read more


HeartBeam Announces Automated Cardiac Detection Patent Granted for HeartBeam AIMIGo™ System

Patent Underscores AI for Vectorcardiography (VECG) IP Leadership Effort SANTA CLARA, Calif. / May 25, 2023 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (VECG) platform intended for patient use at home, today announced it has received a notice of allowance from The United States Patent and Trademark Office for a key patent relating to the initial AI capability in the form... Read more


Invitae Announces CFO Transition and Selection of Veteran Finance Executive Christine Gorjanc as Interim CFO

SAN FRANCISCO, May 25, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that Chief Financial Officer (CFO) Yafei (Roxi) Wen is resigning to pursue other opportunities, effective June 30, 2023. The Company has initiated a search for a new CFO. Ms. Wen will continue in her role through the end of the second quarter. Christine Gorjanc, the Company's longtime Chair of the Audit Committee of the Board of Directors,... Read more


Syneos Health Appoints Batisha Anson to Global Head, Patient Diversity and Health Equity

MORRISVILLE, N.C., May 25, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced the appointment of Batisha Anson to the newly created role of Global Head of Patient Diversity and Health Equity. In this role, Anson will advance Syneos Health’s goal to improve diverse representation of patient populations to provide more equitable access to therapies and innovative science. She will... Read more


23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results

Achieved FY2023 financial guidance FY2023 full year revenue grew 10% over prior year Webcast today, May 25, 2023 at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the fourth quarter (Q4) and full year of... Read more


Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer

Biomarker offers another companion diagnostic option to establish eligibility for FDA-approved drug ELAHERE® SALT LAKE CITY, May 24, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the addition of Folate Receptor Alpha (FRα) to its Precise™ Oncology Solutions portfolio. The new biomarker adds another companion diagnostic option for providers to help guide treatment decisions for... Read more


Global Oncology R&D Activity Remains High and More Patients Have Been Treated for Cancer, says IQVIA Institute for Human Data Science

Spending on cancer medicines is expected to reach $375Bn globally by 2027, up from $196Bn in 2022 For approved medicines, the number of patients treated globally has increased annually by an average of 5% over the past five years Oncology trial starts remained at historically high levels in 2022, up 22% from 2018 Emerging biopharma companies led innovation in oncology in 2022 and account for 71% of the pipeline Oncology clinical trial representation... Read more


Mainz Biomed Processes First Patients from Colorectal Cancer Screening Campaign Through its Corporate Health Portal in Partnership with Zöeller-Kipper

Employees found the online patient portal, through which they ordered the ColoAlert® test, easy-to-use and convenient BERKELEY, Calif. and MAINZ, Germany, May 24, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today initial results from its colorectal cancer (CRC) screening campaign through its BGM (“betriebliches G... Read more


Spectral Medical Hosts Successful Investigator Meeting; Expected to Help Bolster Enrollment Activities

TORONTO, May 24, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today reported hosting an investigator meeting in Charlotte, North Carolina on May 17 - 18, 2023. The in-person meeting was attended by principal investigators (“PI”) and clinical research coordinators (“CRC”) from all existing and new trial sites, as well as... Read more


Biocept Announces Pricing of $5.0 Million Underwritten Public Offering

SAN DIEGO / May 24, 2023 / Business Wire / Biocept, Inc. (NASDAQ: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and service, announces the pricing of an underwritten public offering of 1,176,470 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 2,352,940 shares of its common stock at a combined offering price of $4.25 per share (or pre-funded warrant... Read more


Pluton Biosciences Raises $16.5M Series A led by Illumina Ventures and RA Capital to discover and deploy microbes that will fight climate change

ST. LOUIS, May 24, 2023 /PRNewswire/ -- Pluton Biosciences, a startup leveraging the power of microbes to create cost-effective innovative solutions that address sustainability challenges facing agriculture, announces the close of a $16.5 M Series A funding round. The round was co-led by Illumina Ventures and RA Capital, with participation from existing investors Fall Line Capital, The Grantham Foundation, and First In Ventures, as well as new investors Wollemi, Radicle... Read more


Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results

Delivers solid results; adjusts full-year guidance in an increasingly challenging market Highlights: Revenue of $1.72 billion represents 6.8% reported growth year-over-year; and up 9.5% on a core(1) basis. GAAP net income of $302 million with earnings per share (EPS) of $1.02, up 12% from the second quarter of 2022. Non-GAAP(2) net income of $377 million with EPS of $1.27, up 12% from the second quarter of 2022. Full-year revenue is now expected to be in the range... Read more


T2 Biosystems Announces FDA 510(k) Submission for the T2Biothreat Panel

LEXINGTON, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the Company’s T2Biothreat™ Panel. The FDA submission follows the recently completed U.S. clinical evaluation that demonstrated very high sensitivity and specificity,... Read more


Waters to Present at the Jefferies 2023 Healthcare Conference

MILFORD, Mass., May 23, 2023 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference in New York City on Thursday, June 8th, 2023 at 9:30AM Eastern Time. A live webcast of the event will be available on the 'Events & Presentations' section of Waters' Investor Relations website at https://ir.waters.com. A replay of the webcast... Read more


Twist Bioscience Appoints Robert Werner as Chief Accounting Officer

SOUTH SAN FRANCISCO, Calif. / May 23, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Robert Werner as chief accounting officer. “Rob has a proven track record of leading corporate and technical accounting, including for global companies as they grow in revenue,” said Emily M. Leproust, Ph.D., CEO... Read more

COPYRIGHT ©2023 HEALTH STOCKS HUB